摘要
目的:观察抗癌方辅助治疗中晚期非小细胞肺癌的临床疗效及对肿瘤标志物、凋亡基因和蛋白表达的影响。方法:选取78例中晚期非小细胞肺癌患者为研究对象,随机分为观察组和对照组各39例。对照组采取化疗及对症支持治疗,观察组在对照组基础上辅以抗癌方治疗。对比2组临床疗效及治疗前后肿瘤标志物、凋亡基因和蛋白表达水平,记录不良反应情况。结果:观察组治疗总有效率92.3%,高于对照组的69.2%(P <0.05)。治疗后,2组糖类抗原125 (CA-125)、癌坯抗原(CEA)、神经元特异性烯醇化酶(NSE)以及细胞角蛋白19片断抗原21-1 (CYFRA21-1)水平均较治疗前降低(P <0.05);观察组4项肿瘤标志物水平均低于对照组(P <0.05)。治疗后,2组B淋巴细胞瘤/白血病-2 (Bcl-2)基因表达水平均较治疗前降低(P <0.05),B淋巴细胞瘤/白血病-2基因相关X蛋白(Bax)表达水平均较治疗前提升(P <0.05);观察组Bcl-2基因表达水平低于对照组(P <0.05),Bax表达水平高于对照组(P <0.05)。观察组不良反应发生率12.8%,低于对照组的41.0%(P <0.05)。结论:抗癌方辅助治疗可提高中晚期非小细胞肺癌的治疗效果,其作用机制可能与诱导癌细胞凋亡有关。
Objective:To observe the clinical effect of anti-cancer prescription for advanced non-small cell lung cancer in adjuvant treatment and its influence on tumor markers,apoptosis genes and protein expressions. Methods:Selected 78 cases of patients with advanced non-small cell lung cancer as study subjects,and divided them into the observation group and the control group,39 cases in each group. The control group was given chemotherapy and symptomatic supportive treatment, while the observation group was additionally supplemented with anti-cancer prescription. Compared the clinical effect and the levels of tumor markers,apoptotis genes and protein expressions before and after treatment in the two groups,and recorded adverse reactions. Results:The total effective rate was 92.3% in the observation group,being higher than that of 69.2% in the control group(P<0.05). After treatment,the levels of carbohydrate antigen 125(CA-125),carcinoembryonic antigen (CEA),neuron specific enolase(NSE) and cytokeratin 19 fragment antigen 21-1(CYFRA21-1) in the two groups were decreased when compared with those before treatment(P<0.05);the levels of the four tumor markers mentioned above in the observation group were lower than those in the control group(P<0.05). After treatment,the expression levels of B lymphocytoma/leukemia-2 (Bcl-2) gene in the two groups were decreased when compared with those before treatment(P < 0.05), and the expression levels of gene-associated X protein (Bax) in the B lymphocytoma/leukemia-2 gene were increased when compared with those before treatment(P<0.05);the expression level of Bcl-2 gene in the observation group was lower than that in the control group(P<0.05),and the expression level of Bax was higher than that in the control group(P<0.05). The incidence of adverse reactions in the observation group was 12.8% , being lower than that of 41.0% in the control group (P<0.05). Conclusion: The application of anti-cancer prescription in the adjuvant treatment can improve the curative effect in treating advanced non-small cell lung cancer,and its mechanism may be related to the induction of cancer cell apoptosis.
作者
杨吉荣
傅水桥
YANG Jirong;FU Shuiqiao
出处
《新中医》
CAS
2018年第12期175-177,共3页
New Chinese Medicine
关键词
非小细胞肺癌
中晚期
中西医结合疗法
化疗
抗癌方
肿瘤标志物
细胞凋亡
Non-small cell lung cancer
Advanced stage
Integrated Chinese and western medicine therapy
Chemotherapy
Anti-cancer prescription
Tumor markers
Apoptosis
